Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
14.43 (1y: -4%)
Market Cap 709.6 M P/E(ttm)
Enterprise Value 642.82 M P/B 5.50
OPTR- NAS (USA)
Optimer Pharmaceuticals, Inc.
Not Rated
Top Ranked Predictable Companies
$14.43
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry		 vs
history
Cash to Debt No Debt
OPTR's Cash to Debt is ranked higher than
91% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPTR: No Debt )
OPTR' s 10-Year Cash to Debt Range
Min: 217   Max: No Debt
Current: No Debt
Equity to Asset 0.821
OPTR's Equity to Asset is ranked higher than
80% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. OPTR: 0.821 )
OPTR' s 10-Year Equity to Asset Range
Min: -5.81   Max: 0.87
Current: 0.82
-5.81
0.87
Interest Coverage No Debt
OPTR's Interest Coverage is ranked higher than
96% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPTR: No Debt )
OPTR' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 12.58
M-Score: -4.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry		 vs
history
Operating margin (%) -89.50
OPTR's Operating margin (%) is ranked lower than
57% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. OPTR: -89.50 )
OPTR' s 10-Year Operating margin (%) Range
Min: -6284.4   Max: 3.9
Current: -89.5
-6284.4
3.9
Net-margin (%) -36.4
OPTR's Net-margin (%) is ranked lower than
58% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. OPTR: -36.4 )
OPTR' s 10-Year Net-margin (%) Range
Min: -6015.5   Max: 1805
Current: -36.4
-6015.5
1805
ROE (%) -28.3
OPTR's ROE (%) is ranked lower than
63% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. OPTR: -28.3 )
OPTR' s 10-Year ROE (%) Range
Min: -141.7   Max: 5.4
Current: -28.3
-141.7
5.4
ROA (%) -23.2
OPTR's ROA (%) is ranked lower than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. OPTR: -23.2 )
OPTR' s 10-Year ROA (%) Range
Min: -202.1   Max: 4.3
Current: -23.2
-202.1
4.3
ROC (Joel Greenblatt) (%) -1632.00
OPTR's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. OPTR: -1632.00 )
OPTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1632   Max: 14.9
Current: -1632
-1632
14.9
Revenue Growth (%) 191
OPTR's Revenue Growth (%) is ranked higher than
99% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. OPTR: 191 )
OPTR' s 10-Year Revenue Growth (%) Range
Min: -54.1   Max: 197.4
Current: 191
-54.1
197.4
EBITDA Growth (%) 9.7
OPTR's EBITDA Growth (%) is ranked lower than
95% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. OPTR: 9.7 )
OPTR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 9.7
Current: 9.7
0
9.7
EPS Growth (%) -12
OPTR's EPS Growth (%) is ranked lower than
87% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. OPTR: -12 )
OPTR' s 10-Year EPS Growth (%) Range
Min: -27.9   Max: -1
Current: -12
-27.9
-1
» OPTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

OPTR Guru Trades in Q2 2012

Pioneer Investments 353,394 sh (+8.02%)
Steven Cohen 900,400 sh (-0.12%)
Manning & Napier Advisors, Inc 766,040 sh (-18.31%)
» More
Q3 2012

OPTR Guru Trades in Q3 2012

Manning & Napier Advisors, Inc 787,940 sh (+2.86%)
Pioneer Investments Sold Out
Steven Cohen 587,000 sh (-34.81%)
» More
Q4 2012

OPTR Guru Trades in Q4 2012

Paul Tudor Jones 30,100 sh (New)
Steven Cohen 1,560,107 sh (+165.78%)
Manning & Napier Advisors, Inc Sold Out
» More
Q1 2013

OPTR Guru Trades in Q1 2013

Paul Tudor Jones Sold Out
Steven Cohen 455,977 sh (-70.77%)
» More
» Details

Insider Trades

Latest Guru Trades with OPTR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-09-30 Sold Out 0.0017%$6.96 - $16.87 $ 14.4328%0
George Soros 2011-06-30 New Buy$11.82 - $14.51 $ 14.4311%10200
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Optimer Pharmaceuticals, Inc.

Weekly CEO Sells Highlight: Optimer Pharmaceuticals, ReachLocal, Tractor Supply, and RF Industries
April 14, 2013
According to GuruFocus Insider Data, these are the largest CEO sales of company shares during the past week. Read more...

Ratios

vs
industry		 vs
history
P/B 5.50
OPTR's P/B is ranked higher than
54% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. OPTR: 5.50 )
OPTR' s 10-Year P/B Range
Min: 2.46   Max: 14.92
Current: 5.5
2.46
14.92
P/S 6.50
OPTR's P/S is ranked higher than
72% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. OPTR: 6.50 )
OPTR' s 10-Year P/S Range
Min: 2.98   Max: 745
Current: 6.5
2.98
745
EV-to-EBIT 142.9
OPTR's EV-to-EBIT is ranked lower than
54% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. OPTR: 142.9 )
OPTR' s 10-Year EV-to-EBIT Range
Min: 32.5   Max: 99.7
Current: 142.9
32.5
99.7

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 7.2
OPTR's Price/Net Cash is ranked higher than
85% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.80 vs. OPTR: 7.2 )
OPTR' s 10-Year Price/Net Cash Range
Min: 3   Max: 13.4
Current: 7.2
3
13.4
Price/Net Current Asset Value 41.2
OPTR's Price/Net Current Asset Value is ranked higher than
79% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. OPTR: 41.2 )
OPTR' s 10-Year Price/Net Current Asset Value Range
Min: 11.9   Max: 377
Current: 41.2
11.9
377
Price/Tangible Book 5.3
OPTR's Price/Tangible Book is ranked higher than
72% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. OPTR: 5.3 )
OPTR' s 10-Year Price/Tangible Book Range
Min: 2.9   Max: 12.3
Current: 5.3
2.9
12.3
Earnings Yield (Greenblatt) 0.70
OPTR's Earnings Yield (Greenblatt) is ranked higher than
65% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. OPTR: 0.70 )
OPTR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 3.1
Current: 0.7
0.7
3.1
Forward Rate of Return (Yacktman) -4.21
OPTR's Forward Rate of Return (Yacktman) is ranked higher than
100% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. OPTR: -4.21 )
OPTR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.4   Max: -11.9
Current: -4.21
-19.4
-11.9

Business Description

Optimer Pharmaceuticals, Inc. was incorporated in Delaware on November 18, 1998. It is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products. The Company currently has one anti-infective product, DIFICID (fidaxomicin), which is approved in the United States for the treatment of Clostridium difficile -associated diarrhea ("CDAD") and is developing additional product candidates using its proprietary technology, including its OPopS drug discovery platform. CDAD is the most common nosocomial, or hospital acquired, diarrhea and is not only a significant medical problem in hospitals and long-term care facilities, but is beginning to emerge in the community among people previously at low risk for the disease. CDAD is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. The pharmaceutical industry is highly competitive. The Company faces significant competition from pharmaceutical companies and biotechnology companies that are researching and selling products designed to treat infectious disease.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:XYH.Germany
» More Articles for OPTR

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Optimer Pharmaceuticals, ReachLocal, Tractor Supply, and RF Industries Apr 14 2013 
Optimer Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Optimer Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 03 2010 
Optimer Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2010 
Optimer Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
Weekly CEO Buy Highlights: Helix Energy Solutions Group Inc, Optimer Pharmaceuticals Inc, Keithley I Jan 02 2010 
Optimer Pharmaceuticals Inc. (OPTR) COO and SVP Tessie M Che buys 18,000 Shares Dec 29 2009 
Optimer Pharmaceuticals Inc. (OPTR) CEO Michael N Chang buys 18,000 Shares Dec 29 2009 
Weekly CEO Buys Highlight: Optimer Pharmaceuticals Inc, MBIA Inc, Endeavour International Corp, Dana Dec 05 2009 
Weekly CEO Buys Highlight: Prospect Capital Corp, CONSTELLATION ENERGY, Optimer Pharmaceuticals Inc, Nov 30 2009 

More From Our Partners
Mid-Afternoon Market Update: Optimer Falls as Halozyme Rockets Upwards May 16 2013 - BENZINGA

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial